What did @savvymomlife actually say?
Honestly? Not much that can be fact-checked. The transcript here is song lyrics, not health commentary. The video's actual informational content appears to be lifestyle framing rather than explicit medical claims. What we can assess is the broader context: a postpartum mom tagging Wegovy, GLP-1, and weight loss content, implicitly signaling she's using or considering GLP-1 therapy after having a baby. That framing carries real clinical weight, even without spoken claims.
The hashtags tell a story the lyrics don't. Tagging postpartum, newborn, glp1, and wegovy in the same post sends a message to a vulnerable audience, specifically mothers in the early postpartum period who are looking for weight loss solutions and may not know the safety data on GLP-1 drugs while breastfeeding or soon after delivery.
Does the science back this up?
GLP-1 receptor agonists like semaglutide (Wegovy) do produce meaningful weight loss in clinical trials, but the postpartum context introduces complications that most TikTok content completely ignores.
The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found semaglutide 2.4mg weekly produced an average 14.9% body weight reduction over 68 weeks in adults with obesity. That result is real. But that trial explicitly excluded pregnant and breastfeeding women. Semaglutide is classified as FDA Pregnancy Category X equivalent, meaning it is contraindicated in pregnancy, and its safety profile during lactation is simply unknown because the studies haven't been done.
A 2022 review in Obstetrics and Gynecology (Shulman et al.) noted that GLP-1 receptor agonists pass into breast milk in animal models, and without human lactation data, no safety assurance can be made for breastfed infants. Postpartum timing of GLP-1 initiation is a clinical decision that requires individual evaluation by a licensed provider, not a TikTok trend to follow.
What did they get wrong (or right)?
There are no direct medical claims to rebut from the transcript itself. But the implicit message, that a new mom can casually associate GLP-1 drugs with postpartum life and newborn content, is where the concern lives.
What the video gets right, unintentionally: GLP-1 drugs are prescribed to people in a wide range of life stages, and postpartum weight management is a legitimate medical concern. Gestational weight retention affects long-term cardiometabolic health (Gunderson, 2009, American Journal of Clinical Nutrition), so dismissing postpartum weight concerns entirely would also be wrong.
What deserves pushback: normalizing GLP-1 use in content saturated with newborn and breastfeeding imagery, without any disclaimer about contraindications, does real harm. Viewers who are currently breastfeeding may not realize semaglutide use during lactation is not established as safe. That gap matters.
What should you actually know?
If you're postpartum and thinking about GLP-1 therapy, the conversation starts with your OB or primary care provider, not social media. Here's what that conversation should include.
- Semaglutide (Wegovy, Ozempic) is not approved for use during pregnancy and has no established safety data for breastfeeding women or their infants.
- Most clinical guidelines recommend waiting until after you've stopped breastfeeding before initiating GLP-1 therapy, though the exact timing depends on your individual health picture.
- Postpartum weight retention is a real health issue. The American College of Obstetricians and Gynecologists acknowledges it as a driver of long-term obesity risk, but first-line approaches typically include dietary support and physical activity before pharmacotherapy.
- GLP-1 drugs also suppress appetite significantly, which can affect caloric intake at a time when your body, and potentially your milk supply, depends on adequate nutrition.
The bottom line: the weight loss data for GLP-1 drugs is solid in appropriate populations. The postpartum population simply hasn't been adequately studied, and content that blurs that line without flagging it is doing its audience a disservice.